全文获取类型
收费全文 | 7076篇 |
免费 | 684篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 87篇 |
儿科学 | 225篇 |
妇产科学 | 126篇 |
基础医学 | 960篇 |
口腔科学 | 199篇 |
临床医学 | 756篇 |
内科学 | 1619篇 |
皮肤病学 | 137篇 |
神经病学 | 697篇 |
特种医学 | 181篇 |
外国民族医学 | 2篇 |
外科学 | 1000篇 |
综合类 | 69篇 |
一般理论 | 1篇 |
预防医学 | 645篇 |
眼科学 | 131篇 |
药学 | 379篇 |
中国医学 | 13篇 |
肿瘤学 | 557篇 |
出版年
2023年 | 39篇 |
2022年 | 66篇 |
2021年 | 194篇 |
2020年 | 86篇 |
2019年 | 245篇 |
2018年 | 269篇 |
2017年 | 192篇 |
2016年 | 181篇 |
2015年 | 209篇 |
2014年 | 243篇 |
2013年 | 338篇 |
2012年 | 400篇 |
2011年 | 388篇 |
2010年 | 254篇 |
2009年 | 208篇 |
2008年 | 320篇 |
2007年 | 353篇 |
2006年 | 344篇 |
2005年 | 306篇 |
2004年 | 248篇 |
2003年 | 244篇 |
2002年 | 260篇 |
2001年 | 173篇 |
2000年 | 199篇 |
1999年 | 174篇 |
1998年 | 67篇 |
1997年 | 70篇 |
1996年 | 55篇 |
1995年 | 54篇 |
1994年 | 49篇 |
1993年 | 40篇 |
1992年 | 142篇 |
1991年 | 156篇 |
1990年 | 128篇 |
1989年 | 131篇 |
1988年 | 119篇 |
1987年 | 99篇 |
1986年 | 111篇 |
1985年 | 74篇 |
1984年 | 67篇 |
1983年 | 54篇 |
1981年 | 27篇 |
1980年 | 25篇 |
1979年 | 50篇 |
1977年 | 28篇 |
1976年 | 29篇 |
1974年 | 23篇 |
1973年 | 34篇 |
1970年 | 23篇 |
1969年 | 24篇 |
排序方式: 共有7784条查询结果,搜索用时 0 毫秒
101.
It is currently very rare to find mammary involvement in cases of tuberculosis, in either primary or secondary form. Diagnosis
is classically clinical and microbiological, and the basic techniques used in imaging diagnosis are mammography and ultrasound.
Computed tomography may define the involvement of the thoracic wall in those cases which present as mammary masses adhering
to deep levels, and is also able to evaluate accompanying pulmonary disease, if it is present. Traditionally, treatment has
consisted of quadrantectomy and specific antibiotic therapy. We present a case of tuberculous mammary abscess secondary to
pulmonary disease, which was treated by percutaneous drainage controlled by CT and specific antibiotic therapy. We revise
the diagnosis, differential diagnosis and treatment of mammary tuberculosis.
Received: 27 July 1998; Revision received: 2 February 1999; Accepted: 20 April 1999 相似文献
102.
Prys-Roberts C Lerman J Murat I Taivainen T Lopez T Lejus C Spahr-Schopfer I Splinter W Kirkham AJ 《Anaesthesia》2000,55(9):870-876
We compared the efficacy and safety of a remifentanil (0.25 microg x kg(-1) x min(-1)-based balanced anaesthetic technique with a bupivacaine-based regional anaesthetic technique in an open label, multicentre study in 271 ASA physical status 1 or 2 children aged 1-12 years. Subjects requiring major intra-abdominal, urological or orthopaedic surgery were randomly allocated to receive either intravenous remifentanil (group R; n = 185) or epidural bupivacaine (group B; n = 86) with isoflurane/nitrous oxide for their anaesthesia. The majority of children in both groups (85% in group R, 78% in group B) showed no defined response to skin incision, and although the mean increase in systolic blood pressure (+11 mm Hg) was significantly greater in group R than in group B, this change did not represent a serious haemodynamic disturbance. More children in group R (31%) required interventions to treat hypotension and/or bradycardia than those in group B (12%), but these were easily managed by administration of fluids or anticholinergic drugs. Adverse events, mainly nausea and/or vomiting, occurred in 45% of group R and 42% of group B (NS). The adverse event profile of remifentanil in this study was typical of a potent mu-opioid receptor agonist. Remifentanil was as effective as epidural or caudal block in providing analgesia and suppressing physiological responses to surgical stimuli in children aged between 1 and 12 years undergoing major abdominal, urological, or orthopaedic surgery under isoflurane/nitrous oxide anaesthesia. 相似文献
103.
J.C. Alonso Farto I. Almoguera Arias F.J. Lopez Longo C.M. Gonzalez Fernandez I. Monteagudo Saez A. Ortega Valle M. Bascones J.M. Peréz Vázquez L. Carreño Perez 《European journal of nuclear medicine and molecular imaging》2000,27(12):1768-1773
Abdominal scintigraphy shows silent gut inflammation in patients with spondyloarthropathies (Sp) without clinical evidence of gut inflammation. Abdominal scintigraphy images are different than those obtained in patients with ulcerative colitis or Crohn's disease and are not related to the anti-inflammatory drugs administered. The aim of this study was to examine the clinical associations of findings on abdominal scintigraphy in patients with Sp. A total of 204 Sp patients (European Spondylarthropathy Study Group 1991 criteria) and 54 non-Sp controls receiving non-steroidal anti-inflammatory drugs were studied. Abdominal scintigraphy images were obtained at 30 and 120 min after injection of technetium-99m hexamethylpropylene amine oxime (99mTc-HMPAO)-labelled leucocytes. 99mTc-HMPAO-labelled leucocyte scans were positive in 104 Sp patients (50.9%) and in six non-Sp controls (2.9%) (P<0.001; OR=8.32; 95% CI=3.23-22.67). Silent gut inflammation was not associated with any of the following: age of onset, duration of evolution, sex, family history of Sp or psoriasis, articular manifestations, extra-articular manifestations, radiological findings or HLA-B27 positivity. Positive abdominal scintigraphy was associated with active disease (P<0.0001; OR=52.7; 95% CI=19-145.6) and an increase in the C-reactive protein (P<0.005; OR=3.4; 95% CI=1.5-7.4). It is concluded that (a) abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes is of value in detecting the silent gut inflammation in Sp patients, and (b) silent gut inflammation is related to the clinical activity, but is not associated with any particular type of illness or with HLA-B27. 相似文献
104.
105.
Larry M Lopez 《Journal of the American Pharmacists Association》2005,45(4):503-513
OBJECTIVE: To summarize the relevant pharmacologic, clinical, and safety data regarding rosuvastatin (Crestor--AstraZeneca), the most recently marketed 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor approved for the treatment of dyslipidemia. DATA SOURCES: Medline search from years 1990 thru 2005 using the keywords HMG-CoA reductase inhibitor, hypercholesterolemia, lipid-lowering agents, rosuvastatin, and statins. Study Selection: Review articles, clinical trials, case reports, abstracts, and data on file from the manufacturer concerning rosuvastatin and other statins were considered for inclusion. DATA EXTRACTION: English-language studies were selected for inclusion. DATA SYNTHESIS: Multiple clinical trials have revealed that use of rosuvastatin is associated with greater reductions in low-density lipoprotein cholesterol (LDL-C) across the dose range of 5-40 mg/day than any other currently available statins. Rosuvastatin also significantly increases high-density lipoprotein cholesterol and reduces triglycerides significantly as well. In clinical trials, rosuvastatin was well tolerated, with a low incidence of adverse events and a safety profile similar to that of the other marketed statins. At present, no large-scale primary or secondary prevention clinical trials document either long-term safety of rosuvastatin or its effectiveness in preventing coronary events. CONCLUSION: Compared with other statins, rosuvastatin offers the greatest lipid-lowering efficacy at the lowest dose in treating patients with dyslipidemia and with a similar safety profile over the short-term. Rosuvastatin may allow more patients to achieve their LDL-C goals than any other statin and at a lower dose than other agents. 相似文献
106.
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. 总被引:1,自引:0,他引:1
L Di Lauro F Belli M G Arena S Carpano G Paoletti D Giannarelli M Lopez 《Annals of oncology》2005,16(9):1498-1502
BACKGROUND: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study was designed to evaluate the activity and safety of an epirubicin, cisplatin and docetaxel combination in patients with this disease. PATIENTS AND METHODS: Forty-six patients with gastric adenocarcinoma with measurable distant metastasis were eligible for the study. Patients received epirubicin 50 mg/m(2) and docetaxel 60 mg/m(2), on day 1, and cisplatin 60 mg/m(2) on day 2. Granulocyte colony-stimulating factor 300 mug/day subcutaneously was given on days 5 and 6. Cycles were repeated every 3 weeks for a maximum of eight courses. RESULTS: All patients were evaluable for response and toxicity. Two complete and 21 partial responses were observed, with an overall response rate of 50% [95% confidence interval (CI) 36% to 64%]. Stable disease was observed in 13 patients (28%) and progressive disease in 10 patients (22%). The median time to progression was 6 months (95% CI 5-7) and the median overall survival was 11.2 months (95% CI 8.5-13.9). Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 46%, 7% and 13% of patients, respectively. There were five episodes of febrile neutropenia in four patients. Other grade 3 toxicities included mucositis in three patients (6.5%), vomiting in four patients (8.7%) and diarrhea in one patient (2%). There were no cardiac toxicity, severe neurotoxicity or treatment-related deaths. CONCLUSIONS: The epirubicin, cisplatin and docetaxel combination is an active and well tolerated novel chemotherapy regimen for treating metastatic gastric cancer and deserves further evaluation in randomized studies. 相似文献
107.
Marquis P Vawter Simon Evans Prabhakara Choudary Hiroaki Tomita Jim Meador-Woodruff Margherita Molnar Jun Li Juan F Lopez Rick Myers David Cox Stanley J Watson Huda Akil Edward G Jones William E Bunney 《Neuropsychopharmacology》2004,29(2):373-384
Gender differences in brain development and in the prevalence of neuropsychiatric disorders such as depression have been reported. Gender differences in human brain might be related to patterns of gene expression. Microarray technology is one useful method for investigation of gene expression in brain. We investigated gene expression, cell types, and regional expression patterns of differentially expressed sex chromosome genes in brain. We profiled gene expression in male and female dorsolateral prefrontal cortex, anterior cingulate cortex, and cerebellum using the Affymetrix oligonucleotide microarray platform. Differentially expressed genes between males and females on the Y chromosome (DBY, SMCY, UTY, RPS4Y, and USP9Y) and X chromosome (XIST) were confirmed using real-time PCR measurements. In situ hybridization confirmed the differential expression of gender-specific genes and neuronal expression of XIST, RPS4Y, SMCY, and UTY in three brain regions examined. The XIST gene, which silences gene expression on regions of the X chromosome, is expressed in a subset of neurons. Since a subset of neurons express gender-specific genes, neural subpopulations may exhibit a subtle sexual dimorphism at the level of differences in gene regulation and function. The distinctive pattern of neuronal expression of XIST, RPS4Y, SMCY, and UTY and other sex chromosome genes in neuronal subpopulations may possibly contribute to gender differences in prevalence noted for some neuropsychiatric disorders. Studies of the protein expression of these sex-chromosome-linked genes in brain tissue are required to address the functional consequences of the observed gene expression differences. 相似文献
108.
109.
Scott Caroen Bryan Oronsky Tony Reid Karamjeet Pandher Alric Lopez 《International journal of medical sciences》2022,19(11):1628
RRx-001 is a small molecule NLRP3 inflammasome inhibitor with anti-CD47 and antiangiogenic/vascular normalization properties in a Phase 3 clinical trial that has been designated as a drug-device combination by the FDA. In the Phase 1 first-in-man dose escalation clinical trial, where RRx-001 was given by direct intravenous (IV) infusion, the main adverse event was a sterile painful infusion phlebitis (IP). Less pain was experienced when RRx-001 was infused at a slower rate over multiple hours which was impractical on an outpatient basis. In Phase 2, for reasons of convenience and safety, RRx-001 was co-administered with an aliquot of autologous blood from an ex-vivo device called the eLOOP on the premise that RRx-001 binds to hemoglobin on red blood cells (RBCs), making it unavailable to directly interact with venous nociceptors. Phlebitis has the potential to progress to deep venous thrombosis or septic thrombophlebitis or post-thrombotic syndrome in hypercoagulable and immunosuppressed cancer patients. In this 13-week toxicology study of once weekly IV RRx-001 administration to Wistar Han rats followed by a recovery period of 28 days. The main observed toxicity was a significant inflammatory response in the vein wall, consistent with superficial venous thrombosis observed in man. Due to this development, direct IV infusion of RRx-001 is relatively contraindicated in favor of co-administration with autologous blood. 相似文献
110.
P. Sorrentino S. Petkoski M. Sparaco E. Troisi Lopez E. Signoriello F. Baselice S. Bonavita M.A. Pirozzi M. Quarantelli G. Sorrentino V. Jirsa 《The Journal of neuroscience》2022,42(47):8807
Two structurally connected brain regions are more likely to interact, with the lengths of the structural bundles, their widths, myelination, and the topology of the structural connectome influencing the timing of the interactions. We introduce an in vivo approach for measuring functional delays across the whole brain in humans (of either sex) using magneto/electroencephalography (MEG/EEG) and integrating them with the structural bundles. The resulting topochronic map of the functional delays/velocities shows that larger bundles have faster velocities. We estimated the topochronic map in multiple sclerosis patients, who have damaged myelin sheaths, and controls, demonstrating greater delays in patients across the network and that structurally lesioned tracts were slowed down more than unaffected ones. We provide a novel framework for estimating functional transmission delays in vivo at the single-subject and single-tract level.SIGNIFICANCE STATEMENT This article provides a straightforward way to estimate patient-specific delays and conduction velocities in the CNS, at the individual level, in healthy and diseased subjects. To do so, it uses a principled way to merge magnetoencephalography (MEG)/electroencephalography (EEG) and tractography. 相似文献